Final 8/5/2025 Financial Supplement Second Quarter 2025 This document is a statistical supplement to Aflac's quarterly earnings release. Throughout the presentation, amounts presented may not foot due to rounding. As you review the supplement, please note the non-U.S. GAAP financial measures and definitions found at the back of this document. The Company adopted the Financial Accounting Standards Board's Accounting Standard Update 2018-12 Financial Services - Insurance: Targeted Improvements to the Accounti ...

Exhibit 99.1 Arista Networks, Inc. Reports Second Quarter 2025 Financial Results SANTA CLARA, Calif.- August 5, 2025 -- Arista Networks, Inc. (NYSE: ANET), an industry leader in data-driven, client- to-cloud networking for large AI, data center, campus, and routing environments, today announced financial results for its second quarter ended June 30, 2025. Second Quarter Financial Highlights "Arista is well-positioned in data-driven AI networking, from client to cloud," said Jayshree Ullal, Chairperson and C ...

Exhibit 99.1 Waltham, Mass, August 5, 2025 - Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its second quarter 2025 financial results and provided program and corporate updates. "Spyre is entering a ...

Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up Initiated Phase 2 SKYLINE-UC platform study, evaluating three optimized monotherapies and three potentially paradigm-changing combination ...

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS; UPDATES KEY CLINICAL DEVELOPMENT MILESTONES - Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 - Initiation of a global Phase 2 proof-of-concept clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025 - Cash runway projected to fund operations through 2027 SAN DIEGO – August ...

Exhibit 99.1 IR CONTACT: Leslie Green leslie.green@asteralabs.com Astera Labs Announces Financial Results for the Second Quarter of Fiscal Year 2025 SAN JOSE, CA, U.S. – August 5, 2025 – Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced preliminary financial results for the second quarter of fiscal year 2025, ended June 30, 2025. "Astera Labs delivered strong financial results in Q2 with sequential revenue growth of 20 ...

Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance – Renee Gala named as President and CEO, effective August 11 – – Total revenues of $1.05 billion in 2Q25 – – Xywav revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Zepzelca granted Priority Review in 1L ES-SCLC – ® ® DUBLIN, August 5, 2025 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 ...

Exhibit 99.2 Q2'25 Earnings Results Q2'25 Summary afehold Investment Activity | | Q2'25 Originations | | --- | --- | | | (4 Ground Leases, 3 Leasehold Loans) | | Ground Lease Value1 | $123m | | Leasehold Loan Value2 | $97m | | Markets | 4 (1 New) | | Sponsors | 4 (All New) | | GLTV3a | 33% | | Rent Coverage4a | 3.2x | | Economic Yieldª | 7.2% | Portfolio Metrics5 $6.9b / $9.1b Total Portfolio Aggregate GBV6 / Total Portfolio Estimated UCA Nete: The information in this presentation is as of June 30, 2025, un ...

Amwell ® Announces Results for the Second Quarter Ended June 30, 2025 BOSTON – August 5, 2025 – Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter of 2025. "In Q2, we pursued our strategic initiatives with focus and strong execution. We added Florida Blue, an innovative, large health plan, to our list of strategic clients. We also announced the extension award from the US Defense Health Agen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to ________ Commission File Number: 001-39797 Upstart Holdings, Inc. (Exact name of registrant as specified in its charter) _ ...